Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11982798 | 0.86 | GPR139 (0.43) | GPR139KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL9965803 | 0.81 | KMT2A (0.46) | GPR139KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL19474336 | 0.80 | ALDH1A1 (0.37) | KDM4EPAX8GAALMNAALDH1A1 | |
| SCHEMBL10229011 | 0.78 | KMT2A (0.47) | GPR139KMT2ATSHRLMNAALDH1A1 | |
| SCHEMBL16047247 | 0.78 | KMT2A (0.52) | GPR139KDM4EKMT2AGAATSHR | |
| SCHEMBL19391819 | 0.77 | KMT2A (0.42) | GPR139KDM4EKMT2ATSHRLMNA | |
| SCHEMBL6057117 | 0.77 | GPR139 (0.50) | GPR139KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL19391969 | 0.77 | GPR139 (0.43) | GPR139KDM4EKMT2ATSHRLMNA | |
| SCHEMBL12026008 | 0.77 | KMT2A (0.43) | GPR139KDM4EKMT2ATSHRLMNA | |
| SCHEMBL6662585 | 0.76 | PKM (0.53) | GAALMNAALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147223-A2 | 2'-MODIFIED NUCLEOSIDE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022147214-A2 | CYCLIC-DISULFIDE MODIFIED PHOSPHATE BASED OLIGONUCLEOTIDE PRODRUGS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | BANK OF AMERICA, N.A. | 2019-08-01 | — | — | US | disclosed |
| US-10351852-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | SIRNA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-10000754-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-10000754-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-9957517-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-7205399-B1 | Methods and reagents for oligonucleotide synthesis | SIRNA THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205399-B1 | Methods and reagents for oligonucleotide synthesis | SIRNA THERAPEUTICS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070032441-A1 | treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032441-A1 | treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070004663-A1 | each purine nucleotide is in said siNA is a 2' O-methyl purine nucleotide or each pyrimidine nucleotide in said siNA is a 2'-deoxy-2'-fluoro pyrimidine nucleotide; antisense agents against viral diseases | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004663-A1 | each purine nucleotide is in said siNA is a 2' O-methyl purine nucleotide or each pyrimidine nucleotide in said siNA is a 2'-deoxy-2'-fluoro pyrimidine nucleotide; antisense agents against viral diseases | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004667-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004664-A1 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004664-A1 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004665-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SIRNA THERAPEUTICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662428-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | GPR139 4733/4885KDM4E 4223/4885KMT2A 285/4885 |
| US-20070004663-A1 | each purine nucleotide is in said siNA is a 2' O-methyl purine nucleotide or each pyrimidine nucleotide in said siNA is a 2'-deoxy-2'-fluoro pyrimidine nucleotide; antisense agents against viral diseases | ADAR, NSUN2, SNRPF | GPR139 3434/4885KDM4E 3455/4885KMT2A 553/4885 |
| US-20070032441-A1 | treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | BRCA1, SNRPE, MITF | GPR139 4491/4885KDM4E 4316/4885KMT2A 400/4885 |
| US-20070004664-A1 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | GPR139 4733/4885KDM4E 4223/4885KMT2A 285/4885 |
| US-20070004665-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | GPR139 4591/4885KDM4E 4239/4885KMT2A 414/4885 |
| US-20190194658-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | GPR139 4733/4885KDM4E 4223/4885KMT2A 285/4885 |
| US-10889815-B2 | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) | AGO2, SNRPE, SRRT | GPR139 4733/4885KDM4E 4223/4885KMT2A 285/4885 |
| US-20070004667-A1 | Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability | SNRPE, MSI2, SNRPF | GPR139 4591/4885KDM4E 4239/4885KMT2A 414/4885 |
| US-20190233821-A1 | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) | AGO2, SNRPE, SRRT | GPR139 4733/4885KDM4E 4223/4885KMT2A 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.